Bellerophon Therapeutics, Inc.

Equities

BLPH

US0787713009

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:10:41 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0554 ^USD	+0.73%		+1.84%	+49.73%

Apr. 25	North American Morning Briefing : More Tech -2-	DJ
Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ

Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors

March 04, 2024 at 05:26 pm EST

On March 1, 2024, Mary Ann Cloyd and Dr. Scott Bruder notified Bellerophon Therapeutics, Inc. of their resignation as a member of the Company?s board of directors, effective immediately. Such resignations did not result from any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.

Latest news about Bellerophon Therapeutics, Inc.

North American Morning Briefing : More Tech -2-	Apr. 25	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors	Mar. 04	CI
Bellerophon Therapeutics, Inc. Announces Executive Changes	Nov. 21	CI
Bellerophon Therapeutics, Inc. Announces Executive Changes	Nov. 21	CI
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from S&P TMI Index	23-10-18	CI
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing	23-10-17	MT
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board	23-10-13	CI
Bellerophon Therapeutics, Inc.(OTCPK:BLPH) dropped from NASDAQ Composite Index	23-10-13	CI
North American Morning Briefing : Focus Shifts to -2-	23-08-21	DJ
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading	23-07-28	MT
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director	23-07-14	CI
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023	23-06-29	CI
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) added to Russell 3000E Growth Index	23-06-23	CI
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) added to Russell 3000E Index	23-06-23	CI
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) added to Russell Microcap Growth Index	23-06-23	CI
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) added to Russell Microcap Index	23-06-23	CI
North American Morning Briefing : China Trade Data -2-	23-06-07	DJ
HC Wainwright Adjusts Bellerophon Therapeutics Price Target to $2 From $30, Maintains Buy Rating	23-06-06	MT
Brookline Capital Downgrades Bellerophon Therapeutics to Hold From Buy	23-06-06	MT

Chart Bellerophon Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Companyâs focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Companyâs INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Companyâs subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0554

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BELLEROPHON THERAPEUTICS, INC.	+49.73%	678K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs